TY - JOUR
TI - Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod
AU - Evangelopoulos, M.E.
AU - Miclea, A.
AU - Schrewe, L.
AU - Briner, M.
AU - Salmen, A.
AU - Engelhardt, B.
AU - Huwiler, A.
AU - Chan, A.
AU - Hoepner, R.
JO - CNS Neuroscience and Therapeutics
PY - 2018
VL - 24
TODO - 10
SP - 984-986
PB - Wiley-Blackwell Publishing Ltd
SN - null
TODO - 10.1111/cns.12992
TODO - cyclophosphamide;  fingolimod;  fumaric acid dimethyl ester;  gadolinium;  glatiramer;  liver enzyme;  natalizumab;  rituximab;  fingolimod;  immunosuppressive agent, adult;  adverse outcome;  brain disease;  clinical article;  cohort analysis;  disease course;  disease severity;  drug half life;  drug withdrawal;  epidemiology;  fatigue;  female;  human;  Letter;  lymphocytopenia;  male;  middle aged;  morbidity;  motor dysfunction;  multiple sclerosis;  neoplasm;  neuroimaging;  nuclear magnetic resonance imaging;  patient preference;  phenotype;  recurrent disease;  retrospective study;  risk assessment;  risk factor;  sensory dysfunction;  Switzerland;  treatment withdrawal;  university hospital;  unspecified side effect;  multiple sclerosis;  recurrent disease;  withdrawal syndrome, Adult;  Female;  Fingolimod Hydrochloride;  Humans;  Immunosuppressive Agents;  Male;  Middle Aged;  Multiple Sclerosis;  Recurrence;  Retrospective Studies;  Substance Withdrawal Syndrome
TODO - null
ER -